ATyr Pharma Performance
The firm shows a Beta (market volatility) of 0.14, which signifies not very significant fluctuations relative to the market. As returns on the market increase, ATyr Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding ATyr Pharma is expected to be smaller as well. ATyr Pharma right now shows a risk of 0.0%. Please confirm ATyr Pharma jensen alpha, semi variance, and the relationship between the standard deviation and value at risk , to decide if ATyr Pharma will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ATyr Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, ATyr Pharma is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 10 M | |
| Free Cash Flow | -37.4 M |
ATyr |
ATyr Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in ATyr Pharma on September 27, 2024 and sell it today you would earn a total of 100.00 from holding ATyr Pharma or generate -100.0% return on investment over 90 days. ATyr Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than ATyr, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ATyr Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ATyr Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ATyr Pharma, and traders can use it to determine the average amount a ATyr Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LIFE |
Based on monthly moving average ATyr Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ATyr Pharma by adding ATyr Pharma to a well-diversified portfolio.
ATyr Pharma Fundamentals Growth
ATyr Stock prices reflect investors' perceptions of the future prospects and financial health of ATyr Pharma, and ATyr Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ATyr Stock performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (70.79) % | |||
| Current Valuation | 55.05 M | |||
| Shares Outstanding | 69.01 M | |||
| Price To Earning | (2.19) X | |||
| Price To Book | 1.30 X | |||
| Price To Sales | 334.89 X | |||
| Revenue | 353 K | |||
| EBITDA | (52.18 M) | |||
| Cash And Equivalents | 88.55 M | |||
| Cash Per Share | 3.09 X | |||
| Total Debt | 15.1 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (33.22 M) | |||
| Earnings Per Share | (0.88) X | |||
| Total Asset | 122.07 M | |||
| Retained Earnings | (468.02 M) | |||
| Current Asset | 97.95 M | |||
| Current Liabilities | 12.15 M | |||
About ATyr Pharma Performance
By analyzing ATyr Pharma's fundamental ratios, stakeholders can gain valuable insights into ATyr Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ATyr Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ATyr Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company was incorporated in 2005 and is headquartered in San Diego, California. Atyr Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.Things to note about ATyr Pharma performance evaluation
Checking the ongoing alerts about ATyr Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ATyr Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ATyr Pharma is now traded under the symbol ATYR. Please update your portfolios or report it if you believe this is an error. Report It! | |
| ATyr Pharma is not yet fully synchronised with the market data | |
| ATyr Pharma has some characteristics of a very speculative penny stock | |
| ATyr Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 353 K. Net Loss for the year was (50.39 M) with loss before overhead, payroll, taxes, and interest of (32.42 M). | |
| ATyr Pharma currently holds about 88.55 M in cash with (33.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.09. | |
| Roughly 62.0% of the company shares are owned by institutional investors |
- Analyzing ATyr Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ATyr Pharma's stock is overvalued or undervalued compared to its peers.
- Examining ATyr Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ATyr Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ATyr Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ATyr Pharma's stock. These opinions can provide insight into ATyr Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in ATyr Stock
If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |